# AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC)

Source: https://onco.cc/trials/nct06245915/  
OnCo record `nct06245915` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of AB-2100 in renal cell carcinoma, run by Arsenal Biosciences, Inc., active and no longer recruiting.

## Summary

AB-2100, an Integrated Circuit T Cell Therapy in Patients With Recurrent Clear-cell Renal Cell Carcinoma (ccRCC) is a phase 1/2 interventional study registered as NCT06245915 by Arsenal Biosciences, Inc., with 37 participants enrolled, started 2024-02-26 and due to reach its primary completion in 2026-03-31. Interventions recorded: AB-2100.

## Fields

- Kind: Trial
- Status: active
- Last checked: 2026-09-16
- Tags: pipeline; ctgov-ingest
- Registry id: NCT06245915
- Phase: 1/2
- Setting: An Open-label, Multicenter Phase 1/2 Study to Evaluate the Safety and Efficacy of AB-2100 in Patients With Recurrent Advanced or Metastatic Clear-cell Renal Cell Carcinoma (ccRCC)
- Sponsor: Arsenal Biosciences, Inc.
- Enrolled: 37

## Sources

- ClinicalTrials.gov NCT06245915: https://clinicaltrials.gov/study/NCT06245915

## Connected records

- cancers: [Renal cell carcinoma](https://onco.cc/cancers/rcc/)
- companies: [Arsenal Biosciences](https://onco.cc/companies/arsenal-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct06245915.json